FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...

New research indicates that commonly used measures of kidney function largely underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ...

A study of 1,200 adults with solid tumors presented at ASN Kidney Week 2026 found that creatinine-based and ...

A BMC Pediatrics study finds that a random forest model combining serum creatinine and cystatin C, further improved by adding ...

Oric Pharmaceuticals (NASDAQ:ORIC) reported updated Phase 1b data for enozertinib in previously untreated patients with ...

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways The main tests for kidney disease are an estimated glomerular filtration rate (eGFR) blood test and a urine albumin-to-creatinine ratio (UACR) ...

Enozertinib shows strong efficacy in advanced NSCLC with EGFR atypical mutations, entering Phase 3 trials in 2027. ORIC ...

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% ...

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...

AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have ...

BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines ...

Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September ...